Work | Tumor Initiating Cells
Nifurtimox Phase II Clinical Trial
Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma
Due to the success of the Nifurtimox Phase I Trial, SKC launched a Phase II Clinical Trial in partnership with the University of Vermont on January 14, 2008.
This study offers an important breakthrough by including an additional population of children with medulloblastoma. These patients with medulloblastoma have few therapeutic options and may also potentially benefit from the therapies studied.
As in the Phase I Trial, this study maintains the rational combination of agents (cyclophosphamide and topotecan + nifurtimox) as the best possible design for maximum impact against these cancers.
The Nifurtimox Phase II Trial has also been extended to other cancer centers in the U.S. including St. Louis University/Cardinal Glennon Children’s Medical Center and Children’s Hospital San Diego.
Relevant Articles and Links
Therapeutic Development Project Links
- Nifurtimox Phase I Clinical Trial
- Nifurtimox Phase II Clinical Trial
- Neuroblastoma Drug Discovery Program
- Rapamycin + Vinblastine Phase I Study
- Patient-specific Therapeutic Development for Neuroblastoma
- Oncolytic Virus Program
- Development Program for Neuroblastoma-specific Oncolytic Virus
- Natural Killer Cell Transplant Pilot Study
- Phase I Clinical Trial of HSV Oncolytic Virus